Sentence examples for pharmaceutical development programs from inspiring English sources

Yet, at a recent conference on health care "Economics and Ethics," one participant even suggested that pharmaceutical development programs should not proceed beyond mid-stage clinical trials until the corporate sponsor is assured by reimbursement agencies of a positive coverage decision based on clinical endpoints.

Many pharmaceutical companies are facing a pipeline gap because of the increasing economic burden and uncertainty associated with internal research and development programs designed to develop new pharmaceutical products.

Baucher switched to a new master's program in pharmaceutical development and therapeutic innovation at the University of Poitiers, finishing in 2005.

In Europe and the United States the pharmaceutical industry's drug and vaccine development programs have benefited greatly from using adaptive design in clinical trials as fewer patients are needed and development times can be drastically lowered.

Unfortunately, diseases caused by protozoan parasites, such as trypanosomes, leishmania and plasmodia are not included in research and development programs from the pharmaceutical sector [ 51, 52], resulting in a challenging scenario for the development of new drugs in face of these orphan diseases.

However, many large pharmaceutical companies have cut their research and development programs, which have struggled to produce new drugs over the past decades.

This study provides insight into the cost-effectiveness of biosimilars to academic researchers, pharmaceutical companies that set up biosimilar research and development programs, and policy makers who make decisions about reimbursement of biosimilars.

Pharmaceutical companies are increasingly including pharmacogenomics (PGx) in their drug development programs.

The challenge for pharmaceutical industry, regulators, and academic researchers is to design more efficient and economical clinical development programs to ensure safe and effective medical products.

He participated in Stanford University's NIH-funded graduate training program in biotechnology, including an internship at Genentech, where he is now senior director, pharmaceutical development.

Several pharmaceutical firms, including Alkermes Inc., Parke-Davis, Pfizer, and Novartis, have brought in Mundel to shake up their research and development programs and streamline the process of translating basic research into new drugs.